Vantage logo

Gossamer unravels

The group's pulmonary arterial hypertension therapy might work in sicker patients, but investors are unwilling to stick around.

Vantage logo

Gossamer could put pressure on Merck

The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.